CD274 and esophageal squamous cell carcinoma: To our knowledge, this is the first analysis to consider key PD-L1 expression subgroups aligned with approved indications for the use of tislelizumab + CT in 1L ESCC in the EU (PD-L1 TAP score ≥5%) and the US (PD-L1 ≥1) (13, 15).